Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT-ARBITRATION AWARD

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

On February 22, 2022, Simcere Pharmaceutical Co., Ltd. ("**Simcere Pharmaceutical**"), a subsidiary of the Company, received an arbitration award from Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Center) ("**SHIAC**"). For the Equity Transfer Agreement and the Cooperation Agreement (the "**Agreements**") entered into by Simcere Pharmaceutical with Excel First Limited, Tobishi Pharmaceutical Co., Ltd., and Hirobumi Senga (together as the "**Respondents**") on July 2017, in relation to the dispute on the transfer of 100% of the equity interests in Beijing Tobishi Pharmaceutical Company Co., Ltd. (the "**Target Company**"), SHIAC had the following rulings (the "**Award**"), among others: (i) Excel First Limited may continue its performance to transfer its 100% of the equity interests in the Target Company to Simcere Pharmaceutical; (ii) Tobishi Pharmaceutical Co., Ltd. and Hirobumi Senga have joint and several liabilities associated with the continued performance of obligations under the Equity Transfer Agreement involved. The Award was final and in effect from the date it was made.

On March 27, 2020, due to the breach by the Respondents, SHIAC has made a ruling (the "**Previous Case**") with respect to the Agreements that the Respondents were required to jointly pay for the special damages of RMB50.0 million in accordance with the Agreements. The arbitration award of the Previous Case has not yet been fulfilled by the Respondents.

The Company will closely follow the execution of the Award and any related matters. The Company will make further announcement as and when appropriate to inform the shareholders and potential investors of the Company on the major development of the aforesaid matters.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, February 24, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.